C4 Therapeutics, Inc. Lease, Cost
C4 Therapeutics, Inc. (CCCC) reported Lease, Cost of $10.76 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-02-26
- C4 Therapeutics, Inc. lease, cost for the quarter ending 2022-12-31 was $2.43M, a 138.31% increase year-over-year.
- C4 Therapeutics, Inc. lease, cost for the quarter ending 2022-09-30 was $2.37M, a 169.16% increase year-over-year.
- C4 Therapeutics, Inc. lease, cost for the quarter ending 2022-06-30 was $2.92M, a 281.57% increase year-over-year.
- C4 Therapeutics, Inc. lease, cost for the quarter ending 2021-12-31 was $1.02M.
- C4 Therapeutics, Inc. lease, cost for fiscal 2025 was $10.76M, a 16.35% increase from fiscal 2024.
- C4 Therapeutics, Inc. lease, cost for fiscal 2024 was $9.25M, a 1.96% decline from fiscal 2023.
- C4 Therapeutics, Inc. lease, cost for fiscal 2023 was $9.43M, a 10.82% decline from fiscal 2022.
- C4 Therapeutics, Inc. lease, cost for fiscal 2022 was $10.58M, a 198.50% increase from fiscal 2021.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $10.76M 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $9.25M 10-K · filed 2026-02-26 | |||
| 2023-12-31 | $9.43M 10-K · filed 2025-02-27 | |||
| 2022-12-31 | $2.43M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $4.80M derived: sum of 2 quarters · filed 2024-02-22 | $7.72M derived: sum of 3 quarters · filed 2024-02-22 | $10.58M 10-K · filed 2024-02-22 |
| 2022-09-30 | $2.37M 10-Q · filed 2022-11-03 | $5.29M derived: sum of 2 quarters · filed 2022-11-03 | $8.15M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $2.92M 10-Q · filed 2022-08-04 | $5.78M 10-Q · filed 2022-08-04 | ||
| 2021-12-31 | $1.02M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $1.90M derived: sum of 2 quarters · filed 2023-02-23 | $2.67M derived: sum of 3 quarters · filed 2023-02-23 | $3.54M 10-K · filed 2023-02-23 |
| 2021-09-30 | $882.00K 10-Q · filed 2022-11-03 | $1.65M derived: sum of 2 quarters · filed 2022-11-03 | $2.52M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $765.00K 10-Q · filed 2022-08-04 | $1.64M 10-Q · filed 2022-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |